Differential Epigenetic Effects of BMI Inhibitor PTC-028 on Fusion-Positive Rhabdomyosarcoma Cell Lines from Distinct Metastatic Sites
Tóm tắt
This study aims to deepen our understanding of the novel potential therapeutic target BMI1 (B lymphoma Mo-MLV insert region 1 homolog) in the rare pediatric cancer fusion-positive rhabdomyosarcoma (FP-RMS) and identify gene expression changes that may underlie the loss of cell viability and proliferation that were induced by genetic and pharmacological inhibition of BMI1 in our previous study. FP-RMS cell lines Rh28 and Rh30 were treated with DMSO (vehicle control) or PTC-028, a BMI1 inhibitor, and RNA was collected after 24 or 48 h from three biological replicates. RNA-seq was performed, and differentially expressed gene sets were analyzed by Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway enrichment, and OncoPPi protein–protein interaction data. Many differentially expressed genes in Rh28 and Rh30 belonged to common pathways including downregulation of cell cycle progression, the DNA damage response, and cholesterol biosynthesis. In Rh30 + PTC-028, the majority of the differentially expressed TEAD-motif-containing, Hippo-regulated genes became downregulated. We identified two potential kinases of LATS1/2, EPHA2 and PDGFRA, that become upregulated in PTC-028-treated Rh28 and Rh30 cells. Expression profiling of FP-RMS-derived cell lines suggests that gene expression underlies heterogeneity of FP-RMS. In spite of this heterogeneity, epigenetic intervention through BMI1 elicits an anti-cancer response. Rhabdomyosarcoma (RMS) is a rare pediatric cancer that afflicts hundreds of patients every year. Currently, there are no targeted therapies available for patients with RMS. Our previous work identified a druggable epigenetic protein, BMI1, as a potential therapeutic target. In this study, we investigate the influence of BMI1 inhibitor PTC-028 on developmental pathways and cellular processes through RNA-sequencing. We show that BMI1 inhibition elicits both overlapping and distinct responses in RMS cell lines, indicating inherent differences in these cell lines, though BMI1 inhibition remains an effective therapy. Future works should include epigenetic profiling and additional cell lines and/or patient samples to further understand the influence of BMI1 inhibition in RMS cells.
Tài liệu tham khảo
Skapek SX, Ferrari A, Gupta AA, Lupo PJ, Butler E, Shipley J, et al. Rhabdomyosarcoma. Nat Rev Dis Primers. 2019;5:1.
Amer KM, Thomson JE, Congiusta D, Dobitsch A, Chaudhry A, Li M, et al. Epidemiology, incidence, and survival of rhabdomyosarcoma subtypes: SEER and ICES Database analysis. J Orthop Res. 2019;37:2226–30.
Chen C, Garcia HD, Scheer M, Henssen AG. Current and future treatment strategies for rhabdomyosarcoma [Internet]. Frontiers in Oncology. 2019. Available from: https://doi.org/10.3389/fonc.2019.01458
Arndt CAS, Bisogno G, Koscielniak E. Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned. Cancer Treat Rev. 2018;68:94–101.
Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MCG, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384–9.
Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer. 2009;115:4218–26.
Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol. 2012;30:1670–7.
Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies [Internet]. Nature Reviews Clinical Oncology. 2018. p. 81–94. Available from: https://doi.org/10.1038/nrclinonc.2017.166
Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6:1769–92.
Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh L-S, Lee S-L, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res. 2005;11:3604–8.
Christman JK. 5-Azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–95.
Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl 1):21–9.
Sahasrabuddhe AA. BMI1: A Biomarker of Hematologic Malignancies. Biomark Cancer. 2016;8:65–75.
Bhattacharya R, Mustafi SB, Street M, Dey A, Dwivedi SKD. Bmi-1: At the crossroads of physiological and pathological biology [Internet]. Genes & Diseases. 2015. p. 225–39. Available from: https://doi.org/10.1016/j.gendis.2015.04.001
Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells. 2012;30:372–8.
Park I-K, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004;113:175–9.
Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, et al. Self-renewal as a therapeutic target in human colorectal cancer [Internet]. Nature Medicine. 2014. p. 29–36. Available from: https://doi.org/10.1038/nm.3418
Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G, et al. Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One. 2011;6:e14648.
Kim JH, Yoon SY, Jeong S-H, Kim SY, Moon SK, Joo JH, et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004;13:383–8.
Shields CE, Potlapalli S, Cuya-Smith SM, Chappell SK, Chen D, Martinez D, et al. Epigenetic regulator BMI1 promotes alveolar rhabdomyosarcoma proliferation and constitutes a novel therapeutic target. Mol Oncol [Internet]. 2021; Available from: https://doi.org/10.1002/1878-0261.12914
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621–8.
Gene Ontology Consortium. The gene ontology resource: enriching a GOld mine. Nucleic Acids Res. 2021;49:D325–34.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. Gene Ontol Consortium Nat Genet. 2000;25:25–9.
Rodriguez-Perales S, Martínez-Ramírez A, de Andrés SA, Valle L, Urioste M, Benítez J, et al. Molecular cytogenetic characterization of rhabdomyosarcoma cell lines. Cancer Genet Cytogenet. 2004;148:35–43.
Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003;13:2129–41.
Hinson ARP, Jones R, Crose LES, Belyea BC, Barr FG, Linardic CM. Human rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls. Front Oncol. 2013;3:183.
Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H, et al. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res. 1987;47:4501–7.
Calses PC, Crawford JJ, Lill JR, Dey A. Hippo pathway in cancer: aberrant regulation and therapeutic opportunities. Trends Cancer Res. 2019;5:297–307.
Mo J-S, Park HW, Guan K-L. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014;15:642–56.
Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013;13:246–57.
Ma S, Meng Z, Chen R, Guan K-L. The Hippo pathway: biology and pathophysiology [Internet]. Annual Review of Biochemistry. 2019. p. 577–604. Available from: https://doi.org/10.1146/annurev-biochem-013118-111829
Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer [Internet]. Cancer Cell. 2016. p. 783–803. Available from: https://doi.org/10.1016/j.ccell.2016.05.005
Meng Z, Moroishi T, Guan K-L. Mechanisms of Hippo pathway regulation. Genes Dev. 2016;30:1–17.
Plaisier CL, O’Brien S, Bernard B, Reynolds S, Simon Z, Toledo CM, et al. Causal mechanistic regulatory network for glioblastoma deciphered using systems genetics network analysis. Cell Syst. 2016;3:172–86.
Li Z, Ivanov AA, Su R, Gonzalez-Pecchi V, Qi Q, Liu S, et al. The OncoPPi network of cancer-focused protein–protein interactions to inform biological insights and therapeutic strategies [Internet]. Nature Communications. 2017. Available from: https://doi.org/10.1038/ncomms14356
Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24:1488–501.
Cooper J, Giancotti FG. Molecular insights into NF2/Merlin tumor suppressor function. FEBS Lett. 2014;588:2743–52.
Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O. Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. Genes Chromosomes Cancer. 1996;17:254–9.
Flamier A, Abdouh M, Hamam R, Barabino A, Patel N, Gao A, et al. Off-target effect of the BMI1 inhibitor PTC596 drives epithelial-mesenchymal transition in glioblastoma multiforme. NPJ Precis Oncol. 2020;4:1.
Bolomsky A, Schlangen K, Schreiner W, Zojer N, Ludwig H. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol. 2016;9:17.
Dey A, Xiong X, Crim A, Dwivedi SKD, Mustafi SB, Mukherjee P, et al. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther. 2018;17:39–49.
Buechel M, Dey A, Dwivedi SKD, Crim A, Ding K, Zhang R, et al. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther. 2018;17:2136–43.
Keller C, Guttridge DC. Mechanisms of impaired differentiation in rhabdomyosarcoma. FEBS J. 2013;280:4323–34.
Quach NL, Biressi S, Reichardt LF, Keller C, Rando TA. Focal adhesion kinase signaling regulates the expression of caveolin 3 and beta1 integrin, genes essential for normal myoblast fusion. Mol Biol Cell. 2009;20:3422–35.
Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M, et al. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest. 2009;119:2366–78.
Chen C-L, Paul LN, Mermoud JC, Steussy CN, Stauffacher CV. Visualizing the enzyme mechanism of mevalonate diphosphate decarboxylase. Nat Commun. 2020;11:3969.
Huang B, Song B-L, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132–41.
DepMap: The Cancer Dependency Map Project at Broad Institute [Internet]. [cited 2021 Jun 27]. Available from: https://depmap.org
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607–13.
Eisinger-Mathason TSK, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, et al. Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis. Proc Natl Acad Sci U S A. 2015;112:E3402–11.